Demand remains strong for at least some of Illumina's microarray portfolio, as the company said this week that sales of certain chips contributed to a spike in consumable revenues during the first quarter.

At the same time, Illumina saw microarray instrumentation sales decrease in Q1, causing total array revenue to decline year-over-year, contributing to a 3 percent drop in total revenues compared to the first quarter of 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.